Impact of most promising Ebola therapies on survival: a secondary analysis during the tenth outbreak in the Democratic Republic of Congo

Table 1 Characteristics of patients included in and excluded from the analyses

	Excluded		Included		Overall		p
	n	%	n	%	n	%	p
Age (mean ± SD)	31.03 ± 17.28		29.34 ± 16.24		29.82 ± 16.55		0.124
Gender							0.205
Female	173	54.2	455	58.3	628	57.1
Male	146	45.8	326	41.7	472	42.9
Total	319	100.0	781	100.0	1100	100.0
Profession**							0.058
Others	301	94.4	701	89.8	1002	91.1
Health professionals	16	5.0	69	8.8	85	7.7
Butcher/religious leader	2	0.6	11	1.4	13	1.2
Total	319	100.0	781	100.0	1100	100.0
Type of treatment *							< 0.001
No EVD-specific treatment	0	0.0	55	7.0	55	6.3
MAb114	32	33.3	214	27.4	246	28.1
REGN-EB3	17	17.7	242	31.0	259	29.5
Remdesivir	37	38.5	167	21.4	204	23.3
ZMapp	10	10.4	103	13.2	113	12.9
Total	96	100.0	781	100.0	877	100.0
Vaccine status *							< 0.001
Not received	79	43.2	391	53.9	470	51.7
Received	11	6.0	150	20.7	161	17.7
Unknown	93	50.8	185	25.5	278	30.6
Total	183	100.0	726	100.0	909	100.0
Patient status *							< 0.001
Alive	98	34.6	462	59.2	560	52.6
Deceased	185	65.4	319	40.8	504	47.4
Total	283	100.0	781	100.0	1100	100.0

*: there was missing information; SD: standard deviation; **: occupations classified according to the exposure risk

ISSN: 1743-422X